Navigation Links
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
Date:11/5/2008

Product revenues $28,070 $15,781 $77,752 $43,482

Contract revenues 51 120 1,592 1,197

Total revenues 28,121 15,901 79,344 44,679

OPERATING EXPENSES:

Cost of product revenues 7,140 4,398 19,875 12,417

Research and development 6,939 5,643 20,667 16,037

Selling and marketing 10,837 9,484 35,030 26,377

General and administrative 6,505 4,488 18,635 12,763

Total operating expenses 31,421 24,013 94,207 67,594

Loss from operations (3,300) (8,112) (14,863) (22,915)

Other income (expense):

Interest income 369 1,021 1,438 2,149

Interest and other expense (91) (162) (330) (535)

Net loss ($3,022) ($7,253) ($13,755) ($21,301)

Basic and diluted net

loss per share ($0.11) ($0.26) ($0.49) ($0.81)

Shares used in computing

basic and diluted net

loss per share 28,331,505 28,119,786 28,270,776 26,287,177

Genomic Health, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

September 30, December 31,

2008 2007

(Unaudited) (Audited)

Cash and cash equivalents $9,459 $39,164

Short-term investments 44,965 29,196

Accounts receivable, net 9,423 5,089

Prepaid expenses and other current assets 6,013 3,105

Tota
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... The winners of awards for supply chain ... Global Supply Chain Resiliency Council (GSCRC) at ... February 25th, 2015, at the Hyatt Regency in Santa ... together supply chain risk management and resiliency practitioners with ... through opportunities to collaborate, develop and share best practices, ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
(Date:3/3/2015)... 2015  Rosa & Co. LLC, a drug development ... research, today announced it has two posters scheduled to ... Pharmacology and Therapeutics meeting in New Orleans, ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   Bristol- ... describing a quantitative systems pharmacology approach for immuno-oncology drug ...
(Date:3/3/2015)... March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, announced today that it will ... March 12, 2015 after the market close. The Company will ... day. Interested parties may access the call ... 756-4262 internationally, and using conference ID 98449349.  ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... Mass casualty incidents --,such as terrorist attacks, ... hurricanes -- raise the life-and-death reality that,existing medical ... all who,need it. One of the most critical ... respiratory support., Disaster specialists and health care ...
... CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ), the ... (http://www.MichiganPipeline.com ) is announcing a new service ... their business, or looking to,invest in Michigan ... the existing resources available on the Michigan ...
... PT. RICHMOND, Calif., Oct. 8 Transcept Pharmaceuticals,Inc., ... P. Soloway, Senior Vice President and Chief Financial ... Second Annual Hidden,Gems Conference in New York City ... Time., An audio webcast of the presentation ...
Cached Biology Technology:Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 2Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 3The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... they,ve been sneaking The highly social cichlid ... where non-parents contribute to rearing the offspring of the ... male subordinates never gained paternity in the field. A ... PLoS ONE , reveals that some offspring from ...
... from the University of Utah has received a two-year, $275,000 ... novel research that may help to uncover a viral cause ... These studies will use an advanced technology called deep sequencing ... progressive multiple sclerosis. Multiple sclerosis (MS), which affects an ...
... , The U.S. Food and Drug Administration (FDA) ... Healthcare of Atlanta, Emory University and Saint Joseph,s ... grant to foster the development of medical devices ... award will launch the new Atlanta Pediatric Device ...
Cached Biology News:NIH grant will allow researchers to look for viral cause of most severe form of multiple sclerosis 2FDA grant launches Atlanta Pediatric Device Consortium 2FDA grant launches Atlanta Pediatric Device Consortium 3FDA grant launches Atlanta Pediatric Device Consortium 4
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Dnase and Rnase free...
...
Biology Products: